Science and Research

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel +/- durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

  • Ponce Aix, S.
  • Talbot, D.
  • Govindan, R.
  • Dols, M. C.
  • Postmus, P. E.
  • Lewanski, C.
  • Bennouna, J.
  • Fischer, J. R.
  • Juan-Vidal, O.
  • Stewart, D. J.
  • Ardizzoni, A.
  • Bhore, R.
  • Wolfsteiner, M.
  • Reck, M.
  • Ong, T. J.
  • Morgensztern, D.

Keywords

  • Eortc qlq-c30
  • Eq-5d-5l
  • durvalumab
  • lung cancer symptom scale
  • nab-paclitaxel
  • non-small cell lung cancer
  • quality of life
Publication details
DOI: 10.2217/fon-2019-0796
Journal: Future Oncol
Pages: 749-762 
Number: 12
Work Type: Original
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 32228198
See publication on PubMed

DZL Engagements

chevron-down